
The last few years have seen major shifts in online threats. All companies – including those in biotech – have to take this seriously and respond accordingly. Daniel Schatz, QIAGEN’s Chief Information Security Officer, explains why it’s crucial to reduce a company’s cyber risk by minimizing its online “attack surface”.
icon-cta-blockquote2
Cyberthreats are no longer just the result of hackers directly targeting a company, but also of crossfire from attacks on others.
Daniel Schatz, Chief Information Security Officer of QIAGEN
icon-cta-blockquote2
A strong commitment to cybersecurity is crucial, especially in turbulent times like these. And the best way to approach it is not necessarily as spending on outsourced services, but as investing in the right in-house capabilities.
Daniel Schatz, Chief Information Security Officer of QIAGEN
Our views
-
The world has taken its eye off tuberculosisTuberculosis is highly infectious and a global problem that Covid-19 has only made worse. Two legacies of the response to Covid-19 give rise to hope.
-
RNA, DNA and the rising cost of IP management (Or if too long: The rising cost of IP management)Advances in molecular testing are making patent protection and monitoring ever more difficult. It is time for the sector to reach for new tools.
-
Empower your careerMaking a lateral move to a different department or function can allow you to explore a new opportunity without having to start over completely.